Annals of oncology : official journal of the European Society for Medical Oncology
-
Comparative Study Clinical Trial
Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus.
We have previously reported a favourable response rate in patients with advanced esophageal cancer after treatment with a biweekly regimen of paclitaxel and cisplatin. In this study we investigate the feasibility and efficacy of this regimen in a neo-adjuvant setting. ⋯ This dose-dense schedule of paclitaxel and cisplatin administered biweekly is well tolerated and the observed overall and complete response rates are promising.
-
Practice Guideline Guideline
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of osteosarcoma.